Letters to the Editor

A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial

The University of Texas MD Anderson Cancer Center, Houston, TX
Michigan Medicine - The University of Michigan, Ann Arbor, MI
Dana-Farber Cancer Institute, Boston, MA
Hematology and Stem Cell Transplant Center, AORMN Hospital, Pesaro, Italy
Erasmus Medical Center, Rotterdam, the Netherlands
Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN
The University of Texas MD Anderson Cancer Center, Houston, TX
Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC
Department of Haematology, Aalborg University Hospital, Aalborg, Denmark
Guy’s and St Thomas’ NHS Foundation Trust, London
F. Hoffmann-La Roche, Ltd., Basel
Genentech Inc, South San Francisco, CA
F. Hoffmann-La Roche, Ltd., Basel
F. Hoffmann-La Roche, Ltd., Basel
F. Hoffmann-La Roche, Ltd., Basel
Guy’s and St Thomas’ NHS Foundation Trust, London
Haematologica Early view Jan 25, 2024 https://doi.org/10.3324/haematol.2023.284410